Johnson and Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J., Sept. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Johnso... Biopharmaceuticals Johnson & Johnson, COVID-19, SARS-CoV-2 vaccine

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2046317

Source: HSMN NewsFeed - September 23, 2020 Category: Pharmaceuticals Source Type: news